Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Do not list | Complete | ||
Zavesca | Miglustat | Gaucher disease | Do not list | Complete | ||
Pegasys RBV | Peginterferon alfa-2a and Ribavirin | Hepatitis C, chronic | List in a similar manner to other drugs in class | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Do not list | Complete | ||
Ciprodex | Ciprofloxacin hydrochloride and dexamethasone otic suspension | Otitis media with otorrhea & otitis externa, acute | Do not list | Complete | ||
Gynazole.1 | Butoconazole nitrate | Vaginal infection | Do not list | Complete | ||
Teveten Plus | Eprosartan mesylate/ hydrochlorothiazide | Hypertension, Essential | List in a similar manner to other drugs in class | Complete | ||
Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | Do not list | Complete | ||
Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | ||
Avodart | Dutasteride | Prostatic hyperplasia, benign | List in a similar manner to other drugs in class | Complete |